Bolt Biotherapeutics, Inc.
BOLT
$0.37
$0.0154.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.36% | 35.86% | 64.64% | 67.96% | 37.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.36% | 35.86% | 64.64% | 67.96% | 37.48% |
| Cost of Revenue | -6.62% | 0.01% | -4.32% | -8.53% | -15.84% |
| Gross Profit | 7.24% | 4.70% | 12.20% | 16.77% | 20.37% |
| SG&A Expenses | -18.08% | -11.33% | -1.45% | 2.30% | -1.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.69% | -3.02% | -3.59% | -5.90% | -12.47% |
| Operating Income | 10.45% | 6.63% | 9.26% | 11.77% | 15.64% |
| Income Before Tax | 8.79% | 8.71% | 13.84% | 22.57% | 21.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.79% | 8.71% | 13.84% | 22.57% | 21.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.79% | 8.71% | 13.84% | 22.57% | 21.45% |
| EBIT | 10.45% | 6.63% | 9.26% | 11.77% | 15.64% |
| EBITDA | 10.61% | 6.76% | 9.50% | 12.10% | 16.14% |
| EPS Basic | -13.06% | 9.64% | 14.75% | 23.40% | 22.41% |
| Normalized Basic EPS | -11.10% | 8.09% | 13.33% | 17.75% | 22.42% |
| EPS Diluted | -13.06% | 9.64% | 14.75% | 23.40% | 22.41% |
| Normalized Diluted EPS | -11.10% | 8.09% | 13.33% | 17.75% | 22.42% |
| Average Basic Shares Outstanding | 0.98% | 1.02% | 1.04% | 1.10% | 1.22% |
| Average Diluted Shares Outstanding | 0.98% | 1.02% | 1.04% | 1.10% | 1.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |